Sublingual XXXX as a tocolytic in external cephalic version: a comparative study.

@entity1 @entity12118 @entity390 @entity10 @entity551
OBJECTIVE: To study the effect of sublingual @entity12118 as a tocolytic on the success rate of external cephalic version (ECV) in nulliparous and parous @entity1 . METHODS: A retrospective case-controlled study of all ECV cases from February 1996 to February 2000 in a single centre. The rates of successful ECV were compared between @entity1 who had their ECV before February 1998 (control group), those who had their ECV after February 1998 and received 0.8 mg sublingual @entity12118 spray as a tocolytic agent, and those who had their ECV after February 1998 and received no tocolytic agents. Nulliparous and parous @entity1 were studied separately. Data were collected for parity, gestational age, maternal age, placental localization, and side effects. Chi-square and Kruskal-Wallis tests were performed for statistical comparison. RESULTS: Of 150 @entity1 who had their ECV after February 1998, 120 (80%) received sublingual @entity12118 (group 1: cases using 0.8 mg sublingual @entity12118 spray as a tocolytic agent) and were compared to the 30 @entity1 who did not receive sublingual @entity12118 or other tocolytics after February 1998 (group 2) and to 137 @entity1 who had their ECV before February 1998 (control group). Of the @entity1 who received sublingual @entity12118 , 5 (4%) had @entity551 and 7 (6%) had @entity10 and/or @entity390 . The rate of successful ECV was 27% in group 1 versus 30% in group 2 (p = 0.86) versus 28% in the control group (p = 0.88) for nulliparous @entity1 , and 67% versus 80% (p = 0.30) versus 51% (p = 0.09) respectively for parous @entity1 . However, the success rate was increased overall in parous @entity1 after the introduction of @entity12118 as a tocolytic for ECV in February 1998 (71% vs. 51%, p = 0.02). CONCLUSION: Although the success rate of ECV has increased in recent years, the use of sublingual @entity12118 as a tocolytic was not associated with this higher success rate. A randomized, controlled trial is needed.
